Medical Article

Is a private-label product really better once you factor in performance, durability, and everything it takes to support it? Sometimes yes and sometimes no. The job is knowing the difference. The post Maximizing Value vs. Minimizing Cost in Healthcare Purchasing appeared first on MedCity News.

The takeaway from the current failure of wearables is that signal without synthesis doesn’t change outcomes. If healthcare treats AI as just another way to collect or repackage data, it will repeat the same mistake. The post What the Failure of Wearables Can Teach Us About AI appeared first on MedCity News.

When coordinators are buried in documentation, scheduling, and data reconciliation, patient engagement is the first thing to go. And when engagement drops, retention drops with it. The post Clinical Operations Burnout Is Undermining Patient Enrollment appeared first on MedCity News.

The defining capability of modern health plans is intelligent engagement with unified infrastructure. The post Smarter Engagement for Stronger Growth: How Payers Can Successfully Do More with Less appeared first on MedCity News.

AI genuinely could reduce barriers, by making health information more conversational, more personalized, and easier to act on. But that only happens if the people building these tools decide, from day one, that accessibility isn’t optional. The post AI Is Becoming the Front Door to Healthcare — But Millions of Patients Can’t Get Through It…

A newly diagnosed person experiences healthcare as a complicated maze of physicians, specialists, pharmacies, insurers, deductibles, formularies, prior authorizations, benefit explanations and coverage rules that rarely speak to one another and often contradict each other. Better AI can help. The post AI Made Healthcare Smarter – The Next Step is Making It Simpler appeared first…

Three health systems — Mount Sinai, Michigan Medicine and the University of Kansas Health System — are suing CVS Health, alleging its pharmacy benefit manager diverted roughly $250 million in savings from the 340B program through “spread pricing” between 2020 and 2025. The post Hospitals Take CVS to Court Over Alleged $250M 340B Scheme appeared…

Pharmacies and wholesalers claimed Takeda Pharmaceutical delayed generic competition from entering the market, forcing them to overpay for a gastrointestinal drug. Takeda said the trial had “evidentiary and legal errors,” and the company will appeal the verdict. The post Takeda Vows Appeal of $885M Jury Verdict in ‘Pay-for-Delay’ Antitrust Case appeared first on MedCity News.